Sirius Therapeutics

靖因药业

Develops siRNA (small interfering RNA) therapeutics targeting chronic diseases, with key franchises in coagulation disorders, cardiometabolic diseases and obesity, focused on preventive long-term disease management.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Transfer pricing
• Related-party transactions and balances
• Chapter 18A biotech